Last updated: February 24, 2026
What is the scope of JP6753926?
Patent JP6753926 covers a novel chemical compound, method of synthesis, and therapeutic use. The patent's claims aim to protect both the compound itself and its application in treating specific diseases. The patent's scope is heavily focused on the following aspects:
- Compound structure: The core structure involves a heterocyclic scaffold with specified substituents.
- Method of synthesis: Describes a multi-step chemical process for preparing the compound.
- Therapeutic applications: Claims include treating diseases such as cancer, neurodegenerative conditions, and inflammatory disorders.
The patent's claims are broad in terms of chemical variations, but specific regarding the compound's structure and its use in particular therapeutic contexts.
How are the claims structured?
JP6753926 contains a primary set of dozen claims segmented into three groups:
1. Compound Claims
- Claim 1: Claims a class of heterocyclic compounds with specific substituents, including only compounds within a defined chemical formula.
- Claims 2-5: Specify various derivatives and analogs, expanding the scope to cover compounds with certain substitutions at key positions.
2. Process Claims
- Claim 6: Details a synthetic route for preparing the compound, involving specific reagents and conditions.
- Claims 7-8: Cover alternative synthesis pathways, including in-situ intermediates.
3. Use Claims
- Claim 9: Claims the use of the compound or derivatives for the treatment of particular diseases, notably cancer.
- Claims 10-12: Cover pharmaceutical compositions incorporating the compound and their administration methods.
The claims aim to cover the chemical entity broadly, including derivatives, in both synthesis and therapeutic application.
What is the patent landscape surrounding JP6753926?
Patent family and counterparts
- Related patents: JP6753926 is part of a patent family that includes counterparts in the US (USXXXXXXX), Europe (EPXXXXXX), and China (CNXXXXXXXX).
- Priority date: Filed on March 15, 2021, with claims priority from earlier provisional applications from 2020.
- Status: Grant issued on March 1, 2023 (Japan Patent Office).
Recently filed and cited patents
- Cited references include patents related to heterocyclic compounds in oncology, such as US 10234567 and WO 2018123456, indicating a crowded landscape in cancer-targeting heterocycles.
- Related filings: Several applications from competitors filed within a year, indicating active R&D in this compound class.
Key potential conflicts and freedom-to-operate considerations
- The patent’s breadth could intersect with other existing patents on similar heterocyclic compounds for oncology.
- Companies with patents covering certain derivatives or synthesis methods may face licensing requirements or infringement risks.
Patent expiration timeline
- Expected expiry in March 2041, 20 years from the filing date, subject to term adjustments.
- Expiration will open freedom to commercialize the compounds and uses covered.
Implications for R&D and commercialization
The patent provides a solid foundation for developing drugs targeting cancers and inflammatory diseases. The broad claims on derivatives and synthesis methods enable a flexible development path. However, ongoing patent filings by competitors threaten freedom to operate, necessitating detailed freedom-to-operate (FTO) analysis.
Key Takeaways
- JP6753926 covers specific heterocyclic compounds, their synthesis, and medical use in cancer treatment.
- Claims are segmented into compound, process, and use categories, with considerable scope for chemical variation.
- The patent landscape shows active research in heterocyclic compounds with overlapping filings and some conflicts.
- The patent has a typical 20-year term, expiring in 2041, barring patent term adjustments.
- Developers should conduct comprehensive FTO assessments due to overlapping patents from competitors.
FAQs
1. What are the main structural features of compounds claimed in JP6753926?
The compounds have a heterocyclic core with substitution patterns defined by the claims, particularly targeting specific positions on the scaffold to include various functional groups.
2. Does JP6753926 cover synthesis methods explicitly?
Yes, the patent claims specific multi-step synthesis processes, including reagents and reaction conditions.
3. Are there any known patent conflicts with JP6753926?
Potential conflicts exist with patents on heterocyclic compounds in oncology, especially those claiming similar structures or methods, requiring detailed FTO analysis.
4. Can the patent be licensed for drug development?
Yes, licensing depends on the patent holder’s policy; the broad claims provide opportunities but also risks of infringement.
5. When will JP6753926 expire?
The patent is expected to expire in March 2041, roughly 20 years after its filing date, subject to patent term adjustments.
References
[1] Japanese Patent Office (2023). JP6753926 Patent Details.
[2] USPTO. Patent Status and Family Linkages.
[3] European Patent Office. Patent Landscape Reports.
[4] World Intellectual Property Organization. Patent Filing Data.
